Inflammatory bowel disease is causally related to irritable bowel syndrome: a bidirectional two-sample Mendelian randomization study

From muscle quality to metabolic health: investigating the association between muscle quality index and metabolic syndrome in adults

OBJECTIVE

Metabolic syndrome (MetS) has a high prevalence in the United States (US); however, limited research comprehensively evaluates the relationship between muscle quality index (MQI) and MetS. This study aims to investigate the association between MQI and MetS.

METHODS

Adults aged 20-60 years from the 2011-2014 National Health and Nutrition Examination Survey were included. Handgrip strength (HGS) was measured using a dynamometer, and appendicular skeletal muscle mass (ASM) was assessed via dual-energy X-ray absorptiometry. MQI_total was calculated as the sum of HGS from both hands divided by ASM. Weighted multivariable logistic regression models and restricted cubic splines (RCS) were used to explore the association between MQI_total and MetS, and subgroup, interaction, and sensitivity analyses were conducted.

RESULTS

A total of 4,503 US residents were included in the study, with 1,165 diagnosed with MetS, yielding a prevalence of 25.9% (1,165/4,503). The weighted multivariable logistic regression model indicated that after adjusting for multiple covariates, MQI was negatively associated with the risk of MetS (odds ratio [OR] = 0.49, 95%CI: 0.32-0.73). Among the different components of MetS, MQI was negatively associated with elevated waist circumference (OR = 0.19, 95%CI: 0.12-0.28), elevated high-density lipoprotein cholesterol (OR = 0.66, 95%CI: 0.51-0.85), and elevated serum triglycerides (OR = 0.66, 95%CI: 0.51-0.85). RCS revealed a negative linear relationship between MQI and MetS (P < 0.001, Pnon-linear = 0.98).

CONCLUSION

Low MQI is associated with an increased risk of MetS, exhibiting a linear relationship. These findings suggest that improving muscle quality may be an effective strategy for the prevention of MetS.

Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review

Abdominal pain is a major symptom of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and has a significant impact on patients' quality of life. Given the evolving understanding of IBD pathology and management strategies, there is an urgent need to review the recent research findings. In this review, we have analyzed the epidemiology, pathophysiology, and management of abdominal pain in IBD over the past decade. We draw on the current literature and highlight emerging trends, challenges, and advances in this field. By synthesizing key findings, this review provides insights into the complex interplay between abdominal pain, disease progression, and therapeutic interventions for IBD.

Correlations between genetically predicted lipid-lowering drug targets and inflammatory bowel disease

BACKGROUND

Millions of individuals globally suffer from Inflammatory bowel diseases (IBDs). There is a dearth of large population-based investigations on lipid metabolism and IBDs, and it is unclear whether lipid-lowering drugs target IBDs causally. Consequently, the aim of this study was to investigate the effects of lipid-lowering medication targets on the occurrence and progression of IBDs.

METHODS

Among the more than 400,000 participants in the UK Biobank cohort and the more than 170,000 participants in the Global Lipids Genetics Consortium, a total of nine genes linked to lipid-lowering drug targets were obtained (ABCG5/ABCG8, APOB, APOC3, LDLR, LPL, HMGCR, NPC1L1, PCSK9, and PPARA). IBD data were acquired from de Lange et al. (patients/sample size of IBDs: 25042/59957; ulcerative colitis (UC): 12366/45,975; Crohn's disease (CD): 12194/40,266) and the FinnGen cohort (patients/total sample size of IBDs: 4420/176,899; CD: 1520/171,906; UC: 3325/173,711). All four datasets were cross-combined for validation via Mendelian randomization analysis, and potential mediating factors were explored via mediation analysis.

RESULTS

Genetically proxied APOC3 inhibition was related to increased IBD risk (odds ratio (95% confidence interval): 0.87 (0.80-0.95); P < 0.01) and UC risk (0.83 (0.73-0.94); P < 0.01). IBD and CD risk were reduced by genetic mimicry of LDLR and LPL enhancements, respectively (odds ratioLDLR: 1.18 (1.03-1.36); P = 0.018; odds ratioCD: 1.26 (1.11-1.43); P = 2.60E-04). Genetically proxied HMGCR inhibition was associated with increased CD risk (0.68 (0.50-0.94); P = 0.018). These findings were confirmed through Mendelian analysis of the cross-combination of four separate datasets. APOC3-mediated triglyceride levels may contribute to IBDs partly through mediated triglycerides, Clostridium sensu stricto 1, Clostridiaceae 1, or the Lachnospiraceae FCS020 group. LDLR enhancement may contribute to IBDs partly through increasing Lactobacillaceae.

CONCLUSION

Vigilance is required to prevent adverse effects on IBDs (UC) for patients receiving volanesorsen (an antisense oligonucleotide targeting ApoC3 mRNA) and adverse effects on CD for statin users. LPL and LDLR show promise as candidate drug targets for CD and IBD, respectively, with mechanisms that are potentially independent of their lipid-lowering effects.